Evidence map›Paper›PMID 32217641›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2020

RNA-binding protein altered expression and mislocalization in MS.

Katsuhisa Masaki, Yoshifumi Sonobe, Ghanashyam Ghadge, Peter Pytel, Paula Lépine, Florian Pernin, Qiao-Ling Cui, Jack P Antel, Stephanie Zandee, Alexandre Prat and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 28 citations in OpenAlex.

  1. TDP-43: [GU]-ardian of the transcriptome.Molecular neurodegeneration · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Hypoxia-Induced FUS-circTBC1D14 Stress Granules Promote Autophagy in TNBC.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
  11. Article
  12. Review
  13. Review
  14. Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
  15. Article
  16. Review
  17. Regionally restricted modulation ofFrontiers in molecular neuroscience · 2022
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Katsuhisa MasakiFrom the Department of Neurology (K.M., Y.S., G.G., R.P.R.) and Department of Pathology (P.P.), University of Chicago Medical Center, IL; Neuroimmunology Research Laboratory (P.L., S.Z., A.P.), Centre du Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), QC, Canada; and Neuroimmunology Unit (F.P., Q.-L.C., J.P.A.), Montreal Neurological Institute, McGill University, QC, Canada.
Yoshifumi SonobeFrom the Department of Neurology (K.M., Y.S., G.G., R.P.R.) and Department of Pathology (P.P.), University of Chicago Medical Center, IL; Neuroimmunology Research Laboratory (P.L., S.Z., A.P.), Centre du Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), QC, Canada; and Neuroimmunology Unit (F.P., Q.-L.C., J.P.A.), Montreal Neurological Institute, McGill University, QC, Canada.
Ghanashyam GhadgeFrom the Department of Neurology (K.M., Y.S., G.G., R.P.R.) and Department of Pathology (P.P.), University of Chicago Medical Center, IL; Neuroimmunology Research Laboratory (P.L., S.Z., A.P.), Centre du Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), QC, Canada; and Neuroimmunology Unit (F.P., Q.-L.C., J.P.A.), Montreal Neurological Institute, McGill University, QC, Canada.
Peter PytelFrom the Department of Neurology (K.M., Y.S., G.G., R.P.R.) and Department of Pathology (P.P.), University of Chicago Medical Center, IL; Neuroimmunology Research Laboratory (P.L., S.Z., A.P.), Centre du Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), QC, Canada; and Neuroimmunology Unit (F.P., Q.-L.C., J.P.A.), Montreal Neurological Institute, McGill University, QC, Canada.
Paula LépineFrom the Department of Neurology (K.M., Y.S., G.G., R.P.R.) and Department of Pathology (P.P.), University of Chicago Medical Center, IL; Neuroimmunology Research Laboratory (P.L., S.Z., A.P.), Centre du Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), QC, Canada; and Neuroimmunology Unit (F.P., Q.-L.C., J.P.A.), Montreal Neurological Institute, McGill University, QC, Canada.
Florian PerninFrom the Department of Neurology (K.M., Y.S., G.G., R.P.R.) and Department of Pathology (P.P.), University of Chicago Medical Center, IL; Neuroimmunology Research Laboratory (P.L., S.Z., A.P.), Centre du Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), QC, Canada; and Neuroimmunology Unit (F.P., Q.-L.C., J.P.A.), Montreal Neurological Institute, McGill University, QC, Canada.
Qiao-Ling CuiFrom the Department of Neurology (K.M., Y.S., G.G., R.P.R.) and Department of Pathology (P.P.), University of Chicago Medical Center, IL; Neuroimmunology Research Laboratory (P.L., S.Z., A.P.), Centre du Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), QC, Canada; and Neuroimmunology Unit (F.P., Q.-L.C., J.P.A.), Montreal Neurological Institute, McGill University, QC, Canada.
Jack P AntelFrom the Department of Neurology (K.M., Y.S., G.G., R.P.R.) and Department of Pathology (P.P.), University of Chicago Medical Center, IL; Neuroimmunology Research Laboratory (P.L., S.Z., A.P.), Centre du Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), QC, Canada; and Neuroimmunology Unit (F.P., Q.-L.C., J.P.A.), Montreal Neurological Institute, McGill University, QC, Canada.
Stephanie ZandeeFrom the Department of Neurology (K.M., Y.S., G.G., R.P.R.) and Department of Pathology (P.P.), University of Chicago Medical Center, IL; Neuroimmunology Research Laboratory (P.L., S.Z., A.P.), Centre du Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), QC, Canada; and Neuroimmunology Unit (F.P., Q.-L.C., J.P.A.), Montreal Neurological Institute, McGill University, QC, Canada.
Alexandre PratFrom the Department of Neurology (K.M., Y.S., G.G., R.P.R.) and Department of Pathology (P.P.), University of Chicago Medical Center, IL; Neuroimmunology Research Laboratory (P.L., S.Z., A.P.), Centre du Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), QC, Canada; and Neuroimmunology Unit (F.P., Q.-L.C., J.P.A.), Montreal Neurological Institute, McGill University, QC, Canada.
Raymond P RoosFrom the Department of Neurology (K.M., Y.S., G.G., R.P.R.) and Department of Pathology (P.P.), University of Chicago Medical Center, IL; Neuroimmunology Research Laboratory (P.L., S.Z., A.P.), Centre du Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), QC, Canada; and Neuroimmunology Unit (F.P., Q.-L.C., J.P.A.), Montreal Neurological Institute, McGill University, QC, Canada. rroos@neurology.bsd.uchicago.edu.
University of Chicago Medical Center · US

Funding

Pathogenesis of Theiler's virus-induced demyelinating diseaseR21NS096569 · NINDS · UNIVERSITY OF CHICAGO · PI ROOS, RAYMOND PHILIP · 2016 to 2017
$435k
NINDS NIH HHS R21 NS096569
6 · The paper itself

Abstract

objectiveTo determine whether there are nuclear depletion and cellular mislocalization of RNA-binding proteins (RBPs) transactivation response DNA-binding protein of 43 kDa (TDP-43), fused in sarcoma (FUS), and polypyrimidine tract-binding protein (PTB) in MS, as is the case in amyotrophic lateral sclerosis (ALS) and oligodendrocytes infected with Theiler murine encephalomyelitis virus (TMEV), we examined MS lesions and in vitro cultured primary human brain-derived oligodendrocytes.

methodsNuclear depletion and mislocalization of TDP-43, FUS, and PTB are thought to contribute to the pathogenesis of ALS and TMEV demyelination. The latter findings prompted us to investigate these RBPs in the demyelinated lesions of MS and in in vitro cultured human brain-derived oligodendrocytes under metabolic stress conditions.

resultsWe found (1) mislocalized TDP-43 in oligodendrocytes in active lesions in some patients with MS; (2) decreased PTB1 expression in oligodendrocytes in mixed active/inactive demyelinating lesions; (3) decreased nuclear expression of PTB2 in neurons in cortical demyelinating lesions; and (4) nuclear depletion of TDP-43 in oligodendrocytes under metabolic stress induced by low glucose/low nutrient conditions compared with optimal culture conditions.

conclusionTDP-43 has been found to have a key role in oligodendrocyte function and viability, whereas PTB is important in neuronal differentiation, suggesting that altered expression and mislocalization of these RBPs in MS lesions may contribute to the pathogenesis of demyelination and neurodegeneration. Our findings also identify nucleocytoplasmic transport as a target for treatment.

Indexed as

Active Transport, Cell NucleusStress, PhysiologicalAdultCells, CulturedChildDNA-Binding ProteinsFemaleHumansMaleMiddle AgedMultiple SclerosisOligodendrogliaPolypyrimidine Tract-Binding ProteinRNA-Binding Protein FUSDNA-Binding ProteinsPolypyrimidine Tract-Binding ProteinRNA-Binding Protein FUSTARDBP protein, human

Identifiers

PMID32217641
PMCPMC7176246
OpenAlexW3013277128

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.